medigraphic.com
ISSN 1027-2852 (Digital)
ISSN 0864-4551 (Impreso)

2014, Número 1

Siguiente >>

Biotecnol Apl 2014; 31 (1)


Usos de la inmunoglobulina A en el control de las enfermedades infecciosas

Alvarez N, Sarmiento ME, Mohd-Nor N, Acosta A

Idioma: Ingles.
Referencias bibliográficas: 66
Paginas: 1-6
Archivo PDF: 373.80 Kb.


RESUMEN

La principal puerta de entrada de la mayoría de los microrganismos patógenos es la vía mucosal. Uno de los principales protagonistas inmunológicos en este nivel son las inmunoglobulinas, entre las que prevalece la inmunoglobulina A (IgA). Su función en la protección contra varios agentes patógenos se ha demostrado a partir de la evaluación de sus efectos profiláctico y terapéutico en modelos experimentales y en seres humanos. Sin embargo, aún existen muchas enfermedades infecciosas para las cuales no se ha estudiado la función de la IgA. Por tanto, el campo de aplicaciones de esta inmunoglobulina en enfermedades para las que no existen eficientes métodos de control, permanece abierto a futuras investigaciones. Este artículo trata acerca de las evidencias sobre el uso de la IgA para el control de las enfermedades infecciosas, a partir de observaciones experimentales en modelos animales y seres humanos. La información se obtuvo tras la consulta de artículos científicos sobre la temática, indizados en las bases de datos Pubmed y Google Académico.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Pamer EG. Immune responses to commensal and environmental microbes. Nat Immunol. 2007;8(11):1173-8.

  2. Corthesy B. Multi-faceted functions of secretory IgA at mucosal surfaces. Front Immunol. 2013;4:18.

  3. Kawamura S, Saitou N, Ueda S. Concerted evolution of the primate immunoglobulin alpha-gene through gene conversion. J Biol Chem. 1992;267(11):7359-67.

  4. Alvarez N, Otero O, Camacho F, Borrero R, Tirado Y, Puig A, et al. Passive administration of purified secretory IgA from human colostrum induces protection against Mycobacterium tuberculosis in a murine model of progressive pulmonary infection. BMC Immunol. 2013;14 Suppl 1:S3.

  5. Woof JM, Russell MW. Structure and function relationships in IgA. Mucosal Immunol. 2011;4(6):590-7.

  6. Balu S, Reljic R, Lewis MJ, Pleass RJ, McIntosh R, van Kooten C, et al. A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol. 2011; 186(5):3113-9.

  7. Brown WR, Kloppel TM. The liver and IgA: immunological, cell biological and clinical implications. Hepatology. 1989; 9(5):763-84.

  8. Macpherson AJ, Gatto D, Sainsbury E, Harriman GR, Hengartner H, Zinkernagel RM. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science. 2000;288(5474):2222-6.

  9. Johansen FE, Braathen R, Brandtzaeg P. The J chain is essential for polymeric Ig receptor-mediated epithelial transport of IgA. J Immunol. 2001;167(9):5185-92.

  10. Wieland WH, Orzaez D, Lammers A, Parmentier HK, Verstegen MW, Schots A. A functional polymeric immunoglobulin receptor in chicken (Gallus gallus) indicates ancient role of secretory IgA in mucosal immunity. Biochem J. 2004;380(Pt 3):669-76.

  11. Kaetzel CS, Mostov K. Immunoglobulin transport and the polymeric immunoglobulin receptor. In: Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR, Mayer L, editors. Mucosal Immunology. 3rd ed. Amsterdam: Elsevier/Academic Press; 2005. p. 211-50.

  12. Robinson JK, Blanchard TG, Levine AD, Emancipator SN, Lamm ME. A mucosal IgA-mediated excretory immune system in vivo. J Immunol. 2001;166(6):3688-92.

  13. Strugnell RA, Wijburg OL. The role of secretory antibodies in infection immunity. Nat Rev Microbiol. 2010;8(9):656-67.

  14. Yan H, Lamm ME, Bjorling E, Huang YT. Multiple functions of immunoglobulin A in mucosal defense against viruses: an in vitro measles virus model. J Virol. 2002;76(21):10972-9.

  15. Wright PF. Inductive/effector mechanisms for humoral immunity at mucosal sites. Am J Reprod Immunol. 2011; 65(3): 248-52.

  16. Junqueira LC, Carneiro J. Basic Histology. 10th ed. New York: McGraw-Hill; 2003.

  17. Rashkova M, Baleva M, Toneva N, Jegova G. Secretory immunoglobulin A (S-IgA) and periodontal status in children with diseases and conditions influencing the oral environment. J IMAB Annu Proc. 2009:36-40.

  18. Crottet P, Corthesy B. Secretory component delays the conversion of secretory IgA into antigen-binding competent F(ab’)2: a possible implication for mucosal defense. J Immunol. 1998;161(10):5445-53.

  19. Phalipon A, Cardona A, Kraehenbuhl JP, Edelman L, Sansonetti PJ, Corthesy B. Secretory component: a new role in secretory IgA-mediated immune exclusion in vivo. Immunity. 2002:17(1):107-15.

  20. Ruggeri FM, Johansen K, Basile G, Kraehenbuhl JP, Svensson L. Antirotavirus immunoglobulin A neutralizes virus in vitro after transcytosis through epithelial cells and protects infant mice from diarrhea. J Virol. 1998;72(4):2708-14.

  21. Angel J, Franco MA, Greenberg HB. Rotavirus immune responses and correlates of protection. Curr Opin Virol. 2012; 2(4):419-25.

  22. Brooks HJ, McConnell MA, Corbett J, Buchan GS, Fitzpatrick CE, Broadbent RS. Potential prophylactic value of bovine colostrum in necrotizing enterocolitis in neonates: an in vitro study on bacterial attachment, antibody levels and cytokine production. FEMS Immunol Med Microbiol. 2006;48(3):347-54.

  23. Boullier S, Tanguy M, Kadaoui KA, Caubet C, Sansonetti P, Corthesy B, et al. Secretory IgA-mediated neutralization of Shigella flexneri prevents intestinal tissue destruction by down-regulating inflammatory circuits. J Immunol. 2009;183(9):5879-85.

  24. Perryman LE, Jasmer DP, Riggs MW, Bohnet SG, McGuire TC, Arrowood MJ. A cloned gene of Cryptosporidium parvum encodes neutralization-sensitive epitopes. Mol Biochem Parasitol. 1996;80(2):137-47.

  25. Enriquez FJ, Riggs MW. Role of immunoglobulin A monoclonal antibodies against P23 in controlling murine Cryptosporidium parvum infection. Infect Immun. 1998;66(9):4469-73.

  26. Ivory CP, Chadee K. Intranasal immunization with Gal-inhibitable lectin plus an adjuvant of CpG oligodeoxynucleotides protects against Entamoeba histolytica challenge. Infect Immun. 2007; 75(10):4917-22.

  27. Virdi V, Coddens A, De Buck S, Millet S, Goddeeris BM, Cox E, et al. Orally fed seeds producing designer IgAs protect weaned piglets against enterotoxigenic Escherichia coli infection. Proc Natl Acad Sci USA. 2013;110(29):11809-14.

  28. Longet S, Miled S, Lotscher M, Miescher SM, Zuercher AW, Corthesy B. Human plasma-derived polymeric IgA and IgM antibodies associate with secretory component to yield biologically active secretory-like antibodies. J Biol Chem. 2013;288(6):4085-94.

  29. Mantis NJ, Palaia J, Hessell AJ, Mehta S, Zhu Z, Corthesy B, et al. Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region. J Immunol. 2007;179(5):3144-52.

  30. Moldt B, Saye-Francisco K, Schultz N, Burton DR, Hessell AJ. Simplifying the synthesis of SIgA: Combination of dIgA and rhSC using affinity chromatography. Methods. 2014;65(1):127-32.

  31. Watkins JD, Sholukh AM, Mukhtar MM, Siddappa NB, Lakhashe SK, Kim M, et al. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS. 2013;27(9):F13-20.

  32. Hur EM, Patel SN, Shimizu S, Rao DS, Gnanapragasam PN, An DS, et al. Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice. Blood. 2012;120(23):4571-82.

  33. World Health Organization. Global Tuberculosis Report 2012. 2012 [cited 2013 Aug 18]. Available from: http://apps. who.int/iris/bitstream/10665/75938/ 1/9789241564502_eng.pdf

  34. Reljic R, Crawford C, Challacombe S, Ivanyi J. Mouse monoclonal IgA binds to the galectin-3/Mac-2 lectin from mouse macrophage cell lines. Immunol Lett. 2004;93(1):51-6.

  35. Williams A, Reljic R, Naylor I, Clark SO, Falero-Diaz G, Singh M, et al. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology. 2004;111(3):328-33.

  36. Reljic R, Clark SO, Williams A, Falero- Diaz G, Singh M, Challacombe S, et al. Intranasal IFNgamma extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection. Clin Exp Immunol. 2006;143(3):467-73.

  37. Lopez Y, Yero D, Falero-Diaz G, Olivares N, Sarmiento ME, Sifontes S, et al. Induction of a protective response with an IgA monoclonal antibody against Mycobacterium tuberculosis 16kDa protein in a model of progressive pulmonary infection. Int J Med Microbiol. 2009;299(6):447-52.

  38. Reljic R, Williams A, Ivanyi J. Mucosal immunotherapy of tuberculosis: is there a value in passive IgA? Tuberculosis (Edinb). 2006;86(3-4):179-90.

  39. Boross P, Lohse S, Nederend M, Jansen JH, van Tetering G, Dechant M, et al. IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med. 2013;5(8):1213-26.

  40. Rodriguez A, Tjarnlund A, Ivanji J, Singh M, Garcia I, Williams A, et al. Role of IgA in the defense against respiratory infections IgA deficient mice exhibited increased susceptibility to intranasal infection with Mycobacterium bovis BCG. Vaccine. 2005;23(20):2565-72.

  41. De Groot N, Van Kuik-Romeijn P, Lee SH, De Boer HA. Increased immunoglobulin A levels in milk by over-expressing the murine polymeric immunoglobulin receptor gene in the mammary gland epithelial cells of transgenic mice. Immunology. 2000;101(2):218-24.

  42. Shi J, McIntosh RS, Adame-Gallegos J, Dehal PK, van Egmond M, van de Winkel J, et al. The generation and evaluation of recombinant human IgA specific for Plasmodium falciparum merozoite surface protein 1-19 (PfMSP1 19). BMC Biotechnol. 2011;11:77.

  43. Robins G, Howdle PD. Advances in celiac disease. Curr Opin Gastroenterol. 2005;21(2):152-61.

  44. Ramaprasad P, Fernando A, Madhale S, Rao JR, Edward VK, Samson PD, et al. Transmission and protection in leprosy: indications of the role of mucosal immunity. Leprosy Rev. 1997;68(4):301-15.

  45. Wycoff KL. Secretory IgA antibodies from plants. Curr Pharm Des. 2005;11(19): 2429-37.

  46. Ma JK, Hikmat BY, Wycoff K, Vine ND, Chargelegue D, Yu L, et al. Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nat Med. 1998; 4(5):601-6.

  47. Ambrose CS, Wu X, Jones T, Mallory RM. The role of nasal IgA in children vaccinated with live attenuated influenza vaccine. Vaccine. 2012;30(48):6794-801.

  48. Harris JB, LaRocque RC, Chowdhury F, Khan AI, Logvinenko T, Faruque AS, et al. Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl Trop Dis. 2008;2(4):e221

  49. Sarker SA, Casswall TH, Mahalanabis D, Alam NH, Albert MJ, Brussow H, et al. Successful treatment of rotavirus diarrhea in children with immunoglobulin from immunized bovine colostrum. Pediatr Infect Dis J. 1998;17(12):1149-54.

  50. Weiner C, Pan Q, Hurtig M, Boren T, Bostwick E, Hammarstrom L. Passive immunity against human pathogens using bovine antibodies. Clin Exp Immunol. 1999;116(2):193-205.

  51. Zhang Z, Xiang Y, Li N, Wang B, Ai H, Wang X, et al. Protective effects of Lactobacillus rhamnosus GG against human rotavirus-induced diarrhoea in a neonatal mouse model. Pathog Dis. 2013; 67(3):184-91.

  52. Filler SJ, Gregory RL, Michalek SM, Katz J, McGhee JR. Effect of immune bovine milk on Streptococcus mutans in human dental plaque. Arch Oral Biol. 1991;36(1):41-7.

  53. Thomas JE, Austin S, Dale A, McClean P, Harding M, Coward WA, et al. Protection by human milk IgA against Helicobacter pylori infection in infancy. Lancet. 1993; 342(8863):121.

  54. Ermak TH, Giannasca PJ, Nichols R, Myers GA, Nedrud J, Weltzin R, et al. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med. 1998;188(12): 2277-88.

  55. Crooks CV, Wall CR, Cross ML, Rutherfurd-Markwick KJ. The effect of bovine colostrum supplementation on salivary IgA in distance runners. Int J Sport Nutr Exerc Metab. 2006;16(1):47-64.

  56. Patel K, Rana R. Pedimune in recurrent respiratory infection and diarrhoea -the Indian experience- the pride study. Indian J Pediatr. 2006;73(7):585-91.

  57. Murphy BR. Mucosal immunity to viruses. In: Ogra PL, Mestecky J, Lamm ME, Strober W, McGhee JR, Bienenstock J, editors. Handbook of Mucosal Immunology. New York: Academic Press. 1994; p. 333-43.

  58. Mero A, Kahkonen J, Nykanen T, Parviainen T, Jokinen I, Takala T, et al. IGF-I, IgA, and IgG responses to bovine colostrum supplementation during training. J Appl Physiol (1985). 2002;93(2):732-9.

  59. Hemmingsson P, Hammarstrom L. Nasal administration of immunoglobulin as effective prophylaxis against infections in elite cross-country skiers. Scand J Infect Dis. 1993;25(6):783-5.

  60. Lindberg K, Berglund B. Effect of treatment with nasal IgA on the incidence of infectious disease in world-class canoeists. Int J Sports Med. 1996;17(3):235-8.

  61. Giraudi V, Riganti C, Torales MR, Sedola H, Gaddi E. Upper respiratory infections in children: response to endorsal administration of IgA. Int J Pediatr Otorhinolaryngol. 1997; 39:103-10.

  62. Heikkinen T, Ruohola A, Ruuskanen O, Waris M, Uhari M, Hammarstrom L. Intranasally administered immunoglobulin for the prevention of rhinitis in children. Pediatr Infect Dis J. 1998;17(5):367-72.

  63. Weltzin R, Hsu SA, Mittler ES, Georgakopoulos K, Monath TP. Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice. Antimicrob Agents Chemother. 1994;38(12):2785-91.

  64. Olivares N, Leon A, Lopez Y, Puig A, Cadiz A, Falero G, et al. The effect of the administration of human gamma globulins in a model of BCG infection in mice. Tuberculosis (Edinb). 2006;86(3-4):268-72.

  65. Olivares N, Puig A, Aguilar D, Moya A, Cadiz A, Otero O, et al. Prophylactic effect of administration of human gamma globulins in a mouse model of tuberculosis. Tuberculosis (Edinb). 2009;89(3):218-20.

  66. Rachid R, Bonilla FA. The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature. J Allergy Clin Immunol. 2012;129(3): 628-34.




2020     |     www.medigraphic.com